この記事の概要
To obtain and maintain an FDA license in India, it is important to understand the regulatory environment in India. In India, the term “FDA” is commonly used to refer to the Central Drugs Standard Control Organization (CDSCO), which is the primary regulatory body for the quality, safety and efficacy of drugs and medical devices under the Ministry of Health and Welfare. Agency.
In order to obtain and maintain an FDA license in India, it is important to understand the Indian regulatory environment. The term “FDA” in India usually refers to the Central Drugs Standard Control Organization ( CDSCO ), which is the primary agency under the Indian Ministry of Health and Welfare that regulates the quality, safety, and efficacy of drugs and medical devices under the Indian Ministry of Health and Welfare.

FDA Licensing Process
- Preparation of the application dossier: Depending on the product, we prepare all the necessary technical details, including clinical trial data, manufacturing processes, quality control, and safety information.
- Filing: Filing an application with CDSCO in the appropriate category, e.g., new drug, generic drug, medical device, imported drug, etc.
- Review: CDSCO will review the submitted data and may request additional information in some cases. The review process may include an inspection of the manufacturing facility as well as a scientific evaluation.
- Approval: Once all criteria are met, a license is issued. The license is valid for a fixed period of time and must be renewed.
License Maintenance
- Periodic Renewals: Licenses usually need to be renewed after a certain period of time. Renewal applications must provide updated information on the safety and validity of the product.
- Quality assurance and compliance with manufacturing standards: International manufacturing standards such as GMP (Good Manufacturing Practices) must be met on an ongoing basis.
- Post-market surveillance: Even after a product is on the market, side effects and defects must be reported, and recalls and updated safety information must be implemented as necessary.
- Communication with Regulators: Regular communication with regulators is required to ensure prompt response to new regulatory requirements and changes in guidelines.
Obtaining and maintaining an FDA license in India is a complex and time-consuming process, often requiring specialized expertise, and the assistance of a professional regulatory consultant is recommended. In addition, local legal and regulatory assistance is essential to adapt and comply with India’s unique regulatory requirements.
畠山 聡先生 (はたやま さとし)
医師・医学博士 / ヒロクリニック医師
略歴
- 2016年 大阪市立大学(現:大阪公立大学)卒業
- 2016年 育和会記念病院
- 2019年 大阪鉄道病院
- 2021年 大阪公立大学附属病院
- 2022年 大阪鉄道病院医長
- 2023年 ヒロクリニックなんば心斎橋院院長
資格・所属
- 日本泌尿器科学会認定の泌尿器科専門医
この記事は、ヒロクリニックEDの編集・監修体制にもとづき、資格を持つ医師が内容を確認しています。


